Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
XEN723
Cat. No.:
OB0225LY-0225
Appearance:
Solid
Purity:
≥99%
Identity:
Confirmed by NMR, HPLC, and LC-MS.
Size:
Product Overview
Description:
XEN723 is a compound used to probe pain mechanisms and affects nociceptive perception primarily by modulating sodium channel activity.
Synonym:
1072803-08-7; 2-(3-(4-Fluorobenzyl)-2-oxoimidazolidin-1-yl)-4-methyl-N-(pyridin-3-ylmethyl)thiazole-5-carboxamide; 2-[3-[(4-Fluorophenyl)methyl]-2-oxoimidazolidin-1-yl]-4-methyl-N-(pyridin-3-ylmethyl)-1,3-thiazole-5-carboxamide; 2-{3-[(4-Fluorophenyl)methyl]-2-oxoimidazolidin-1-yl}-4-methyl-N-(pyridin-3-ylmethyl)-1,3-thiazole-5-carboxamide
CAS No.:
1072803-08-7
Compound CID:
25095149
Formula:
C21H20FN5O2S
Formula Weight:
425.48
Specification
Relative Density:
1.384 g/cm3
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
XEN723 can be used in pain physiology studies or play an important role in neuroscience research.
Library Information
Targets:
Stearoyl-CoA desaturase (SCD) family
Receptors:
SCD1
Pathways:
Metabolism
Plate Number:
AOCL-3
Plate Location:
g9
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10 mM DMSO
DMSO Max Solubility:
100 mg/mL; 235.03 mM
